Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GELATO trial: atezolizumab + carboplatin in metastatic lobular breast cancer
2017-001428-23Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in Invasive Lobular Carcinoma (ILC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Progression-free at 6 months (overall). Started Jun 2017; status: active.
02
Drugs
atezolizumab
03
Conditions
Invasive Lobular Carcinoma (ILC)
Beyond the preview
Go deeper on 2017-001428-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001428-23.